No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome
- PMID: 37328621
- PMCID: PMC10541531
- DOI: 10.1007/s00259-023-06293-2
No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome
Abstract
Purpose: The benefit from attenuation and scatter correction (ASC) of dopamine transporter (DAT)-SPECT for the detection of nigrostriatal degeneration in clinical routine is still a matter of debate. The current study evaluated the impact of ASC on visual interpretation and semi-quantitative analysis of DAT-SPECT in a large patient sample.
Methods: One thousand seven hundred forty consecutive DAT-SPECT with 123I-FP-CIT from clinical routine were included retrospectively. SPECT images were reconstructed iteratively without and with ASC. Attenuation correction was based on uniform attenuation maps, scatter correction on simulation. All SPECT images were categorized with respect to the presence versus the absence of Parkinson-typical reduction of striatal 123I-FP-CIT uptake by three independent readers. Image reading was performed twice to assess intra-reader variability. The specific 123I-FP-CIT binding ratio (SBR) was used for automatic categorization, separately with and without ASC.
Results: The mean proportion of cases with discrepant categorization by the same reader between the two reading sessions was practically the same without and with ASC, about 2.2%. The proportion of DAT-SPECT with discrepant categorization without versus with ASC by the same reader was 1.66% ± 0.50% (1.09-1.95%), not exceeding the benchmark of 2.2% from intra-reader variability. This also applied to automatic categorization of the DAT-SPECT images based on the putamen SBR (1.78% discrepant cases between without versus with ASC).
Conclusion: Given the large sample size, the current findings provide strong evidence against a relevant impact of ASC with uniform attenuation and simulation-based scatter correction on the clinical utility of DAT-SPECT to detect nigrostriatal degeneration in patients with clinically uncertain parkinsonian syndrome.
Keywords: 123I-FP-CIT; Attenuation correction; Dopamine transporter; Ioflupane; SPECT; Scatter correction.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures


Similar articles
-
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis.Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):213-27. doi: 10.1007/s00259-012-2276-8. Epub 2012 Nov 16. Eur J Nucl Med Mol Imaging. 2013. PMID: 23160999
-
Utility of Follow-up Dopamine Transporter SPECT With 123I-FP-CIT in the Diagnostic Workup of Patients With Clinically Uncertain Parkinsonian Syndrome.Clin Nucl Med. 2017 Aug;42(8):589-594. doi: 10.1097/RLU.0000000000001696. Clin Nucl Med. 2017. PMID: 28574876
-
Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis.Ann Nucl Med. 2019 Jan;33(1):14-21. doi: 10.1007/s12149-018-1297-1. Epub 2018 Oct 1. Ann Nucl Med. 2019. PMID: 30276622 Free PMC article.
-
Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):424-38. doi: 10.1007/s00259-007-0621-0. Epub 2007 Oct 30. Eur J Nucl Med Mol Imaging. 2008. PMID: 17968545 Review.
-
A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice.Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1974-1987. doi: 10.1007/s00259-023-06171-x. Epub 2023 Feb 27. Eur J Nucl Med Mol Imaging. 2023. PMID: 36847827 Free PMC article.
Cited by
-
Fully automatic categorical analysis of striatal subregions in dopamine transporter SPECT using a convolutional neural network.Ann Nucl Med. 2025 Jun;39(6):618-630. doi: 10.1007/s12149-025-02038-3. Epub 2025 Mar 16. Ann Nucl Med. 2025. PMID: 40089953 Free PMC article.
-
Incorporating label uncertainty during the training of convolutional neural networks improves performance for the discrimination between certain and inconclusive cases in dopamine transporter SPECT.Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1535-1548. doi: 10.1007/s00259-024-06988-0. Epub 2024 Nov 27. Eur J Nucl Med Mol Imaging. 2025. PMID: 39592475 Free PMC article.
-
The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023.Nuklearmedizin. 2025 Aug;64(4):250-261. doi: 10.1055/a-2566-1487. Epub 2025 Apr 15. Nuklearmedizin. 2025. PMID: 40233814 Free PMC article.
References
-
- Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, et al. Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging. 2016;43:1315–1322. doi: 10.1007/s00259-015-3304-2. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous